Recursion Pharmaceuticals, Inc. RXRX Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s other commercial liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported other commercial liabilities of $54.21M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s other commercial liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s other commercial liabilities decreased by 4.6% year-over-year, from $56.8M to $54.21M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s other commercial liabilities has grown at a 46.3% compound annual growth rate (CAGR), from $10.49M to $70.23M.